Preciseinhale, the next-generation R&D platform, appears at SOT 2014

  • 16 mars, 2014
  • 16:10

At 2014’s Annual SOT (Society of Toxicology) conference Inhalation Sciences will present a poster on spray drying micronization system LaminarPace, plus their next-generation research platform PreciseInhale. Company founder, Dr Per Gerde explains how the platform was developed through intense environmental and toxicological research.

Toxicological and environmental respiratory research is built into the DNA of Inhalation Sciences’ flagship technology PreciseInhale. The paradigm shifting inhalation R&D platform was developed at the elite Lovelace Respiratory Research Institute in the 1990s as part of founder Dr Per Gerde’s research into radioactive diesel dust dosimetry in the lungs.

What does the system offer environmental respiratory researchers?

Dr Gerde: “Scarcity of material and a need for respirable aerosol is a particularly acute problem in the study of toxic airborne particles. With PreciseInhale you can produce realistic aerosol exposures from minute amounts of collected / available study materials. Study materials can be collected and selected from the environment or manufactured in a lab – but they are nearly always highly expensive. Even with industrial granular materials you need to select out that minuscule fraction that is actually respirable – and that costs money. We can get results from tiny amounts of substance. PreciseInhale typically uses between 50 – 100 mg of test substance for a full PK study.”

Risk assessments of carcinogenic substances

Dr Gerde collaborated on Dr Pär Ewing’s research into the metabolic dose response of inhaled model particles in the lungs using the Isolated Perfused Lung (Toxicological Sciences, 2006.) This research influenced the development of the multi-module capabilities of today’s PreciseInhale platform, which can deliver data from dry powder or inhalers, from a wide range of modalities – cell cultures in vitro, isolated perfused lung, in vivo, nose-only or intratracheal inhalation.

Innovation, expertise, experience

Dr Gerde: “Some scientists may associate us primarily with generating powders for inhalation drug development. But a large part of our work has always been toxicological, environmental research. We continue to play a significant role and offer major quality benefits in this arena for government, private and public/private research initiatives from around the world. If you are carrying out research into environmental respiratory pollutants we offer outstanding innovation, expertise, experience and scientific quality. Come and meet us at SOT in Phoenix.”

At SOT Inhalation Sciences will present a poster on LaminarPace, its spray drying micronization system. Product Development Manager for Formulation Dr. Fernando Acevedo:

“We run a lot of tests for environmental agency research on noxious environments,” says Dr. Acevedo. “Separating particles to see how they are noxious in the environment and exactly how they behave in the lungs. For many people our public profile has been about generating powders for inhalation drug development, but a significant percentage of our work has always been toxicological, environmental research too.”

For environmental respiratory researchers PreciseInhale delivers:

Milligrams not grams: Minimal test substance required

PreciseInhale typically uses between 50 – 100 mg of costly test substance for a full PK study. Powders are de?agglomerated and aerosolized so efficiently that an even distribution in the lungs can be achieved from less than 100 mg of test substance.

Months not years: Active dosing delivers indicative data earlier

PreciseInhale uses active dosing, a one- animal-at-a-time system that typically delivers data with a dosing precision of SD 5 – 15%. Compared to multiple animal exposure systems it reduces both the number of animals,  and the time needed for trials and R&D. 

Maximum versatility: Dry powders or inhaler

PreciseInhale is built in two units, an aerosol generator and a dispensing unit. The aerosol dispensing unit can also connect to any inhaler on the market, delivering aerosols to a wide range of exposures models, from cell cultures to rodents, up to dogs and humans. 


Dr Gerde started developing what is today PreciseInhale, at the Lovelace Respiratory Research Institute as part of his research into radioactive diesel dust dosimetry in the lungs: “I needed an aerosol generator sophisticated enough to validate theoretical model predictions on radioactive diesel dust dosimetry in the lungs. It had to be able to generate an aerosol that would deliver high-quality data and minimum particle agglomeration from the smallest amounts of powder. Such a system did not then exist – so I began building it.”